Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval
AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.
You may also be interested in...
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.